RT Journal Article
SR Electronic
T1 Protection of Hamsters Challenged with SARS-CoV-2 Variants of Concern by Two Doses of MVC-COV1901 Vaccine Followed by a Single Dose of Beta Variant Version of MVC-COV1901
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.09.29.462344
DO 10.1101/2021.09.29.462344
A1 Kuo, Tsun-Yung
A1 Lien, Chia-En
A1 Lin, Yi-Jiun
A1 Lin, Meei-Yun
A1 Wu, Chung-Chin
A1 Tang, Wei-Hsuan
A1 Campbell, John D.
A1 Traquina, Paula
A1 Chuang, Ya-Shan
A1 Liu, Luke Tzu-Chi
A1 Chen, Charles
YR 2021
UL http://biorxiv.org/content/early/2021/10/15/2021.09.29.462344.abstract
AB The current fight against COVID-19 is compounded by the Variants of Concern (VoCs), which can diminish the effectiveness of vaccines and potentially increase viral transmission and severity of disease. MVC-COV1901 is a protein subunit vaccine based on the prefusion SARS-CoV-2 spike protein (S-2P) and is adjuvanted with CpG 1018 and aluminum hydroxide. In this study, we used the Delta variant to challenge hamsters inoculated with S-2P from the Wuhan wildtype and the Beta variant in two-dose or three-dose regimens. Two doses of wildtype S-2P followed by the third dose of Beta variant was shown to induce the highest neutralizing antibody titer against live SARS-CoV-2 of the wildtype as well as all current VoCs. All regimens of vaccination were able to protect hamsters from SARS-CoV-2 Delta variant challenge and resulted in reduced lung live virus titer and pathology. Three doses of vaccination also significantly reduced lung viral RNA titer, regardless of whether the wildtype or Beta variant S-2P was used as the third dose. Based on the immunogenicity and viral challenge data, two doses of wildtype S-2P followed by the third dose of Beta variant S-2P induced a broad and potent immune response against the Alpha, Beta, Gamma, and Delta variants.Competing Interest StatementC. C., T.-Y. K., C.-C. W., W.-.H. T, C.-E. L., Y.-J. L., and M.-Y. L. are co-inventors for US provisional patent applications 63/240,408, 63/240,080, and 63/248,189.